Roche Diagnostics Licenses Melting Curve Analysis Technique to Eppendorf
News Oct 31, 2007
Under the terms of the agreement, Eppendorf obtains from Roche a non-exclusive license to use, develop and sell products based on Melting Curve Analysis; excluded from the rights is the use in human and veterinary in vitro diagnostics.
Financial terms of the agreement were not disclosed.
The melting curve analysis is a technique for analysis of PCR products. After PCR, the resulting PCR product is slowly heated. Each double-stranded DNA has its own specific melting temperature (Tm), which is defined as the temperature at which 50% of the DNA becomes single stranded. By measurement of Tm, the DNA can be easily identified.
“We regard the licensing of the melting curve analysis technique as an important contribution to further developing this technology in the life science field,” states Manfred Baier, Head of Roche Applied Science, a business area of Roche Diagnostics.
“This agreement provides both companies, Eppendorf and Roche Diagnostics, with potential for continuing their success in this field,” adds Michael Schroeder, Board Member Sales and Marketing Eppendorf AG.
In July this year, Roche and Eppendorf already signed a cooperation agreement in the field of protein expression.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.